ABSTRACT
Brain magnetic resonance imaging (MRI) has identified a high incidence of cerebral ischemia in asymptomatic patients after atrial fibrillation (AF) ablation (silent). Detection of cerebral ischemic events on MRI is based on acute hyperintense lesions on diffusion-weighted imaging. In the literature, the incidence is related to specifications of MRI and depends on the definition applied. In comparative studies, silent cerebral events (SCE, diffusion-weighted MRI [DWI] positive only) appear to be approximately 3 times more common compared to using a definition of silent cerebral lesions (SCL; without fluid attenuated inverse recovery sequence [FLAIR] positivity). Whereas the FLAIR sequence may turn positive within days after the ischemic event, SCE definition is highly sensitive for early phases of ischemic brain damage. SCE/SCL appear to represent cerebral ischemic infarcts and determine the "embolic fingerprint" of a specific ablation technology and strategy used. The optimum time point for detecting SCE is early after AF ablation (24-72 hours), whereas detection of SCL can only be performed within the first 2-7 days (due to delay of FLAIR positivity). Different technology-, procedure-, and patient-related parameters have been identified to play a role in the multifactorial genesis of SCE/SCL. In recent years, evidence has been gathered that there may be differences of SCE/SCL rates depending upon the ablation technology used, but small patient numbers and a large number of potential confounders hamper all studies. As major findings of recent studies, mode of periprocedural and intraprocedural anticoagulation has been identified as a major predictor for incidences of SCE/SCL. Whereas procedural characteristics related to higher SCE/SCL-rates may be modified, unchangeable patient-related factors should be taken into account for future individualized risk assessment. Novel ablation devices introduced into the market should be tested for their potential embolic fingerprint and refinements of ablation procedures to reduce their embolic potential should be prompted. The knowledge of "best practice" in terms of low SCE/SCL rates has prompted changes in work-flow, which have been implemented into ablation procedures using novel ablation devices. So far, no study has linked SCE/SCL to neuropsychological decline and the low number of AF-ablation-associated events needs to be weighted against the multitude of preexisting asymptomatic MRI-detected brain lesions related to the course of AF itself. Future studies are needed to evaluate if more white matter hyperintensities due to AF may be prevented by AF ablation (producing only a small number of SCE/SCL).
Subject(s)
Atrial Fibrillation/surgery , Brain Ischemia/etiology , Catheter Ablation/adverse effects , Intracranial Embolism/etiology , Asymptomatic Diseases , Atrial Fibrillation/diagnosis , Atrial Fibrillation/physiopathology , Brain Ischemia/diagnosis , Consensus , Diffusion Magnetic Resonance Imaging , Humans , Intracranial Embolism/diagnosis , Predictive Value of Tests , Risk Assessment , Risk Factors , Time Factors , Treatment OutcomeABSTRACT
In recent years, ablation therapy has become the first-line treatment of modern electrophysiology in patients with cardiac arrhythmias. Today, cardiac magnetic resonance imaging (cMRI) is an important supportive imaging technique in the implementation of complex electrophysiological investigations and ablation therapy. In clinical routine, cMRI is used not only to generate accurate three-dimensional (3D) models of cavities of the heart but also for visualization of complex anatomical structures. The development of cMRI makes it possible to detect the underlying substrate of complex arrhythmias such as myocardial scar in patients with ventricular tachycardia or the structural remodeling of the left atrium in patients with atrial fibrillation. The opportunity of fusion of the different imaging modalities (e.g., fluoroscopy, cMRI) has become essential for the planning and the implementation of a safe ablation therapy. The possibility of direct visualization of induced lesions using cMRI after and in the long term after ablation can predict the success of therapy and detects potential complications. The continuous research in the field of cMRI and the development of MRI-compatible pacing and ablation catheters provided the basics for performing electrophysiological treatment in humans directly inside the MRI. The implementation of ablation using exact visualization of the anatomical substrate, precise catheter navigation and real-time visualization of lesions in cMRI promises to improve success rates and the safety of complex ablation treatment and may revolutionize electrophysiology in the future.
